Abstracts Archive - Page 836 of 2607 - ACR Meeting Abstracts

Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: L05 • ACR Convergence 2020
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Kaleb Michaud¹, Sofia Pedro², Kristin Wipfler³, Ekta Agarwal⁴ and Patricia Katz⁵, ¹University of Nebraska Medical Center and Forward, the National Databank for Rheumatic Diseases, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Pfizer inc, Princeton Jct, NJ, ⁵UCSF, Mill Valley, CA
Background/Purpose: To understand medication and clinical care changes by patients with RA during the first 3 months (March through May 2020) of the COVID-19 pandemic…
Abstract Number: L06 • ACR Convergence 2020
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Maria C. Cid¹, Sebastian Unizony², Lara Pupim³, Fang Fang⁴, Joseph Pirrello³, Ai Ren⁴, Manoj Samant⁴, Teresa Zhou⁴ and John F Paolini⁴, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Massachusetts General Hospital, Boston, MA, ³Kiniksa Pharmaceuticals, Lexington, MA, ⁴Kiniksa Pharmaceuticals, Lexington
Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
Abstract Number: L07 • ACR Convergence 2020
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
John Stone¹, ¹Massachusetts General Hospital, Boston, MA
Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
Abstract Number: L08 • ACR Convergence 2020
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Thomas MacDonald¹, Isla Mackenzie¹, George Nuki² and Ian Ford³, ¹University of Dundee, Dundee, Scotland, United Kingdom, ²University of Edinburgh, Edinburgh, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Dinesh Khanna¹, Christopher Denton², Daniel Furst³, Maureen Mayes⁴, Marco Matucci-Cerinic⁵, Vanessa Smith⁶, Dick de Vries⁷, Liesbeth Deberdt⁸, Pieter‑Jan Stiers⁸, Niyati Prasad⁸ and Sohail Ahmed⁹, ¹University of Michigan, Ann Arbor, MI, ²Royal Free Hospital, University College London, London, United Kingdom, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Università degli Studi di Firenze, Firenze, Italy, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Galapagos BV, Leiden, Netherlands, ⁸Galapagos NV, Mechelen, Belgium, ⁹Ahmed Science Medicine, Basel, Switzerland
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Victoria Werth¹, Jodi Karnell², William Rees², Nanette Mittereder³, Li Yan², Yanping Wu³, Jorn Drappa², Gabor Illei² and John Ratchford², ¹University of Pennsylvania, Philadelphia, PA, ²Viela Bio, Gaithersburg, MD, ³Viela Bio, Gaithersburg
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
Abstract Number: L11 • ACR Convergence 2020
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Atul Deodhar¹, Paula Sliwinska-Stanczyk², Huji Xu³, Xenofon Baraliakos⁴, Lianne Gensler⁵, Dona Fleishaker⁶, Lisy Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Cunshan Wang⁶, Oluwaseyi Dina⁷, Lara Fallon⁸, Keith S Kanik⁶ and Désirée van der Heijde⁹, ¹Oregon Health & Science University, Portland, OR, ²Reumatika Centrum Reumatologii, Warszawa, Poland, ³Shanghai Changzheng Hospital, Shanghai, China (People's Republic), ⁴Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany, ⁵University of California San Francisco, San Francisco, CA, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Montreal, QC, Canada, ⁹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.Methods: This Phase 3, randomized, double-blind…
Abstract Number: 0001 • ACR Convergence 2020
Management of Rheumatic Diseases During COVID-19: A National Veterans Affairs Survey of Rheumatologists
Jasvinder Singh¹, John Richards², Elizabeth Chang³, Amy Joseph⁴ and Bernard Ng⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ³PVAHCS, Phoenix, AZ, ⁴Washington University / St. Louis VA, Saint Louis, MO, ⁵VA Puget Sound HCS, Seattle, WA
Background/Purpose: To assess the experience, views and opinions of rheumatology providers at Veterans Affairs (VA) facilities about rheumatic disease healthcare issues during the COVID-19 pandemic.Methods:…
Abstract Number: 0002 • ACR Convergence 2020
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
Cristiano Moura¹, Marina Machado¹, Celline Almeida-Brasil¹, Jeffrey R Curtis², Kevin Winthrop³, Michal Abrahamowicz¹ and Sasha Bernatsky⁴, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Oregon Health & Science University, Portland, OR, ⁴The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…
Abstract Number: 0003 • ACR Convergence 2020
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Quinn Pritchett¹, Rebecca Overbury¹, Dorota Lebiedz-Odrobina¹, Julie Thomas¹, Tawnie Braaten², Stacey Clardy¹, Marc Elgort³, Emily Spivak¹, Patricia Slev³, Lisa Peterson³ and Tracy Frech⁴, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, ³ARUP, Salt Lake City, UT, ⁴University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
Abstract Number: 0004 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries
Nelly Ziade¹, Lina El Kibbi², Ihsane Hmamouchi³, Nizar Abdulateef⁴, Hussein Halabi⁵, Wafa Hamdi⁶, Fatemah Abutiban⁷, Manal el Rakawi⁸, Mervat Eissa⁹ and Basel Masri¹⁰, ¹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ²Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ³Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, ⁴Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Iraq, Baghdad, Iraq, ⁵King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁶Department of Rheumatology, Kassab Institute of orthopedics, UR17SP04, Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia, Tunis, Tunisia, ⁷Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah hospital, State of Kuwait, Jahra, Kuwait, ⁸Departement of Rheumatology, Douera Hospital, Faculty of Medicine, Saad Dahlab, Blida, Algeria, Blida, Algeria, ⁹Rheumatology Department, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Jordan Hospital, Amman, Jordan, Amman, Jordan
Background/Purpose: To evaluate the impact of the Coronavirus Disease 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases in…
Abstract Number: 0005 • ACR Convergence 2020
Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists
Bella Mehta¹, Deanna Jannat-Khah², Carol Mancuso³, Anne Bass¹, Carine Moezinia⁴, Allan Gibofsky³, Susan Goodman⁵ and Said Ibrahim⁶, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York City, NY, ³Hospital for Special Surgery, New York City, ⁴Hospital for Special Surgery, New York, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Weill Cornell Medicine, Cleveland, OH
Background/Purpose: To investigate the perceptions and behaviors of rheumatologists in the United States (US) regarding the risk of COVID-19 for their autoimmune patients and the…
Abstract Number: 0006 • ACR Convergence 2020
Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Milena Gianfrancesco¹, Liza Leykina², Zara Izadi³, Carly Harrison⁴, Suleman Bhana⁵, Wendy Costello⁶, Rebecca Grainger⁷, Jonathan Hausmann⁸, Jean Liew⁹, Emily Sirotich¹⁰, Paul Sufka¹¹, Zachary Wallace¹², Gabriela Schmajuk¹³, Pedro M Machado¹⁴, Philip Robinson¹⁵ and Jinoos Yazdany¹⁶, ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴Lupus Chat, NA, ⁵Crystal Run Health, Middletown, ⁶Irish Children's Arthritis Network, Tipperary, Ireland, ⁷University of Otago, Wellington, New Zealand, ⁸Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ⁹University of Washington, Seattle, WA, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Healthpartners, St Paul, ¹²Massachusetts General Hospital, Newton, MA, ¹³University of California, San Francisco, Atherton, CA, ¹⁴University College London, London, United Kingdom, ¹⁵University of Queensland, Herston, Queensland, Australia, ¹⁶UCSF, San Francisco, CA
Background/Purpose: Individuals with rheumatic disease, particularly those on immunosuppressive medications, have a higher risk of developing severe infections. However, whether these patients experience more severe…
Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Emily Sirotich¹, Kevin Kennedy², Salman Surangiwala³, Teresa Semalulu¹, Maggie Larche¹, Jean Liew⁴, Zachary Wallace⁵, Philip Robinson⁶, Rebecca Grainger⁷, Jeffrey Sparks⁸, Julia Simard⁹, Jinoos Yazdany¹⁰, Monique Gore-Massy¹¹, Richard Howard¹², Mitchell Levine² and Jonathan Hausmann¹³, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³Queen’s School of Medicine, Kingston, Canada, ⁴University of Washington, Seattle, WA, ⁵Massachusetts General Hospital, Newton, MA, ⁶University of Queensland, Herston, Queensland, Australia, ⁷University of Otago, Wellington, New Zealand, ⁸Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁹Stanford Medicine, Stanford, CA, ¹⁰UCSF, San Francisco, CA, ¹¹Lupus Foundation of America, Brooklyn, NY, ¹²Spondylitis Association of America, Van Nuys, CA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].